<?xml version="1.0" encoding="UTF-8"?>
<ref id="ref57">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Griffin</surname>
    <given-names>M. P.</given-names>
   </name>
   <name>
    <surname>Khan</surname>
    <given-names>A. A.</given-names>
   </name>
   <name>
    <surname>Esser</surname>
    <given-names>M. T.</given-names>
   </name>
   <name>
    <surname>Jensen</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Takas</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Kankam</surname>
    <given-names>M. K.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2017</year>). 
  <article-title>Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults</article-title>. 
  <source>Antimicrob. Agents Chemother.</source>
  <volume>61</volume>, 
  <fpage>e01714</fpage>â€“
  <lpage>e01716</lpage>. 
  <pub-id pub-id-type="doi">10.1128/AAC.01714-16</pub-id>
  <pub-id pub-id-type="pmid">27956428</pub-id>
 </mixed-citation>
</ref>
